LIVN — LivaNova PLC stock price, charts and financials

QT72LivaNova PLC

LivaNova PLC (NASDAQ: LIVN) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
78.01
+0.22+0.28%
OverviewShort InterestFilings
LIVNQT72LivaNova PLC·NASDAQ
78.01+0.28%
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ITGR-0.04%$126.28HAE+0.74%$108.40IRTC-2.17%$109.33TMDX-0.28%$86.42NEOG+1.32%$13.00AXGN-2.34%$44.23INSP+5.55%$76.78UFPT+0.46%$276.69
Snapshot
Index-P/E23.01EPS (ttm)3.39Insider Own1.14%Shs Outstand54.93MPerf Week-0.22%
Market Cap4.29BForward P/E16.68EPS next Y4.68Insider Trans-2.09%Shs Float54.70MPerf Month-3.50%
Enterprise Value4.11BPEG1.17EPS next Q1.04Inst Own-Short Float9.12%Perf Quarter-0.62%
Income189.00MP/S2.91EPS this Y28.48%Inst Trans-Short Ratio7.10Perf Half Y22.79%
Sales1.47BP/B3.23EPS next Y7.37%ROA7.14%Short Interest4.99MPerf YTD26.78%
Book/sh24.12P/C8.29EPS next 5Y19.59%ROE15.41%52W High85.76 -9.04%Perf Year43.06%
Cash/sh9.41P/FCF28.95EPS past 3/5Y-ROIC10.19%52W Low48.82 59.79%Perf 3Y36.91%
Dividend Est.-EV/EBITDA22.72Sales past 3/5Y10.74% 8.25%Gross Margin68.18%Volatility2.51% 2.59%Perf 5Y-5.86%
Dividend TTM-EV/Sales2.79EPS Y/Y TTM192.24%Oper. Margin13.48%ATR (14)2.23Perf 10Y28.69%
Dividend Ex-Date-Quick Ratio1.21Sales Y/Y TTM17.48%Profit Margin12.82%RSI (14)44.32Recom2.33
Dividend Gr. 3/5Y-Current Ratio1.45EPS Q/Q20.00%SMA20-2.04%Beta0.86Target Price88.50
Payout0.00%Debt/Eq0.40Sales Q/Q10.76%SMA50-2.42%Rel Volume2.07Prev Close77.79
Employees3,300LT Debt/Eq0.37EarningsNov 04SMA20010.36%Avg Volume666.94KPrice78.01
IPO DateOct 19, 2015Option/ShortYes / YesEPS/Sales Surpr.15.12% 2.65%Net Debt/EBITDA-0.91Volume1,377,456Change0.28%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-02-26ReiteratedPiper SandlerOverweight$85 → $90
Aug-05-26ReiteratedStifel NicolausBuy$80 → $85
Aug-05-26ReiteratedNeedhamBuy$81 → $93
Jul-15-26ReiteratedMizuhoOutperform$90 → $95
Jun-22-26ReiteratedKeybancOverweight$81 → $92
May-07-26ReiteratedMizuhoOutperform$72 → $90
May-07-26ReiteratedBarclaysEqual Weight$67 → $76
Feb-25-26ReiteratedStifel NicolausBuy$70 → $80
Feb-25-26ReiteratedNeedhamBuy$88 → $81
Feb-19-26ReiteratedPiper SandlerOverweight$85
Latest News· Times ET
Sep-17-26
Sep-17-2612:39AM
Squarepoint Ops LLC Acquires Shares of 17,242 LivaNova PLC $LIVNdefenseworld.net
Sep-15-26
Sep-15-2607:01AM
LivaNova Director Trades $273K In Company StockBenzinga
Sep-14-26
Sep-14-2609:31AM
LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com
Sep-10-26
Sep-10-2604:55PM
LivaNova Director Sells 1,650 Shares for $131,500fool.com
Sep-09-26
Sep-09-2608:51AM
LivaNova PLC (NASDAQ:LIVN) Combines Strong Growth With a Timely Technical SetupChartMill
Sep-02-26
Sep-02-2608:33AM
Piper Sandler Reiterates Overweight on LivaNova, Raises Price Target to $90Benzinga
Aug-25-26
Aug-25-2606:34AM
LivaNova: Careful About The Valuation And UpsideSeekingAlpha
Aug-18-26
Aug-18-2608:30AM
LivaNova (NASDAQ:LIVN) Combines Strong Growth With a Promising Technical Breakout SetupChartMill
Aug-14-26
Aug-14-2611:21PM
LivaNova PLC $LIVN Stake Lessened by Bank of America Corp DEdefenseworld.net
Aug-12-26
Aug-12-2607:16PM
Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)Yahoo
Aug-10-26
Aug-10-2612:15AM
Dynatronics (NASDAQ:DYNT) vs. LivaNova (NASDAQ:LIVN) Critical Reviewdefenseworld.net
Aug-06-26
Aug-06-2609:36AM
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raisedzacks.com
Aug-05-26
Aug-05-2609:30AM
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcriptseekingalpha.com
09:05AM
LivaNova Q2 Earnings Call Highlightsmarketbeat.com
06:31AM
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com
Company

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,4721,3881,253——————
Cost of Goods Sold Incl. D&A468448383——————
Gross Profit1,004940871——————
Selling, General and Administrative Excl. Other584549526——————
Research and Development204186183——————
Other Operating Expense17633——————
Operating Income199199129——————
Interest Expense464963——————
Unusual Expense
—————————
Non-Operating Income (Expense)-45-37122——————
Net Income Before Taxes108-22188——————
Income Taxes-822225——————
Consolidated Net Income189-24263——————
Net Income From Continuing Operations189-24263——————
Net Income189-24263——————
EPS (Recurring)3.45-4.451.17——————
EPS (Basic, Before Extraordinaries)3.45-4.451.17——————
EPS (Diluted)3.39-4.451.16——————
EBITDA181-129203——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio23.01—39.92——————
Price To Sales Ratio2.912.442.00——————
Gross Margin68.2167.7269.51——————
Operating Margin13.5214.3410.30——————
Net Margin12.84-17.445.03——————
Shares Outstanding555554——————
Market Capitalization4,2913,3842,501——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$91.96$77.59$63.23$48.86$34.50● Close Price0.00K115.08K230.15K345.23K460.30KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bianchi FrancescoDirectorSep 10 '26Sale78.013,500273,0324,434Sep 14
Story BrookeDirectorSep 04 '26Sale81.422,300187,2707,488Sep 08
Bianchi FrancescoDirectorAug 31 '26Sale79.721,650131,5387,934Sep 02
Tezel AhmetChief Innovation OfficerAug 11 '26Option Exercise52.6812,692668,61518,782Aug 13
Tezel AhmetChief Innovation OfficerAug 11 '26Sale77.742,675207,9426,090Aug 13
WILVER PETER MDirectorJun 15 '26Option Exercise0.004,042010,780Jun 17
SCHERMERHORN TODD CDirectorJun 15 '26Option Exercise0.004,042013,105Jun 17
Bianchi FrancescoDirectorJun 15 '26Option Exercise0.004,042011,270Jun 17
Bianchi FrancescoDirectorJun 15 '26Sale80.191,20096,2289,584Jun 17
PODLOGAR SUSAN MDirectorJun 15 '26Option Exercise0.004,04206,128Jun 17
Barry James ChristopherDirectorJun 15 '26Option Exercise0.004,04208,404Jun 17
Tezel AhmetChief Innovation OfficerJun 15 '26Option Exercise0.002,96507,122Jun 17
KOZY WILLIAM ADirectorJun 15 '26Option Exercise0.005,681038,248Jun 17
Enxing Seng StacyDirectorJun 15 '26Option Exercise0.004,042015,793Jun 17
Story BrookeDirectorJun 15 '26Option Exercise0.004,042010,274Jun 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.